Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

Major Program(s) or Research Group(s)

  • Chemopreventive Agent Development
  • Phase 0/I/II Cancer Prevention Clinical Trials Program

Sponsor

National Cancer Institute (NCI)

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02052908

This randomized phase Ib trial studies the side effects and best dose of naproxen in
preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in
patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from
forming. The use of naproxen may keep cancer from forming in patients with Lynch syndrome.

Intervention

Laboratory Biomarker Analysis, Naproxen, Placebo Administration

Condition

Lynch Syndrome

Investigators

Eduardo Vilar-Sanchez

See list of participating sites